Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price gapped up prior to trading on Monday . The stock had previously closed at $11.29, but opened at $12.20. Telix Pharmaceuticals shares last traded at $11.80, with a volume of 197,400 shares traded.

Key Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pixclara (floretyrosine F 18, or 18F-FET), an amino-acid PET imaging drug designed to help image gliomas, a form of brain cancer. The approval covers both adult and pediatric patients and gives Telix access to the U.S. market for this diagnostic product. FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
• Positive Sentiment: The approval may improve investor expectations for Telix’s revenue growth and strengthen its position in molecular imaging, although the eventual financial impact will depend on commercial launch timing, physician adoption and reimbursement. FDA green light for Telix’s brain cancer imaging drug Pixclara
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and assigned a $22 price target, signaling substantial expected upside and adding further positive analyst support following the FDA decision.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TLX. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, September 2nd. Royal Bank Of Canada cut Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Finally, Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Monday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Stock Performance

The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The company’s fifty day simple moving average is $11.23 and its 200-day simple moving average is $10.16.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers boosted its holdings in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Telix Pharmaceuticals in the 4th quarter worth approximately $89,000. Bank of America Corp DE lifted its position in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares during the period. OLD Mission Capital LLC bought a new position in shares of Telix Pharmaceuticals during the 4th quarter worth approximately $111,000. Finally, XY Capital Ltd acquired a new stake in Telix Pharmaceuticals in the 1st quarter valued at $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.